Conference Call Scheduled for Monday, May 9, 2016 at 4:30pm ET

NEWARK, Calif., April 25, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the Company will release first quarter 2016 financial results on Monday, May 9, 2016 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30pm PT/4:30pm ET on the same day to discuss the results and provide a business and pipeline update.

Individuals interested in listening to the conference call may do so by dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for international callers and reference conference ID: 87895155; or from the webcast link in the investor relations section of the Company's website at: www.revance.com.

A replay of the call will be available beginning May 9, 2016 at 4:30pm PT/7:30pm ET through midnight on May 10, 2016. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 87895155. The webcast will be available in the investor relations section on the Company's website for 30 days following the completion of the call.

About Revance Therapeutics, Inc.
Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science.  The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology.  Revance’s trajectory to commercial success begins with the company’s novel and proprietary TransMTS® carrier-peptide delivery system, which is uniquely designed to target and transport macromolecules to their desired location.

Revance’s journey to market starts with the neurotoxin daxibotulinumtoxinA, the company’s highly purified botulinum toxin type A.  The TransMTS technology is used in the delivery of botulinum toxin through two novel drug product candidates:  DaxibotulinumtoxinA Topical Gel (RT001) that permits needle-free application, and DaxibotulinumtoxinA for Injection (RT002), which is designed to enable targeted administration and long-lasting effect.

Revance is developing RT001 and RT002 for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles, excessive sweating and muscle movement disorders. The company holds worldwide rights for all indications of RT001, RT002 and the TransMTS technology platform.  Beyond botulinum toxin, Revance expects the TransMTS technology can be applied to transdermal, mid-dermal or deep tissue delivery of a variety of other macromolecules.  More information on Revance can be found at www.revance.com.

"Revance Therapeutics", TransMTS®, “Remarkable Science Changes Everything”, and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

Contacts 
Investors:
Revance Therapeutics
Jeanie Herbert
(714) 325-3584
jherbert@revance.com

Burns McClellan
Ami Bavishi
212-213-0006
abavishi@burnsmc.com

Trade Media:
Nadine Tosk
504.453.8344
nadinepr@gmail.com